99.7% remained HIV negative

with DESCOVY®.


A proven HIV prevention option they can love.

5 dancing figures.

Long-term results over 144 weeks1-4

Primary endpoint and 96-week analysis: Randomized, double-blind study of HIV seronegative MSM and TGW receiving once-daily DESCOVY FOR PrEP® (n=2694) or FTC/TDF (n=2693). Baseline to ≥144 weeks analysis: DESCOVY participants in double-blind phase entering an additional ≥48-week OLE (n=2070).

Noninferior HIV incidence rate through 96 weeks1-4

At primary analysis*: 0.16/100 PY vs 0.34/100 PY. At 96 weeks: 0.16/100 PY vs 0.30/100 PY.
99.7% vs 99.4% of participants remained HIV negative at both time points.
At ≥144 weeks: 0.14/100 PY; 99.5% of participants remained HIV negative with DESCOVY.

Safety profile through 144 weeks1,2,4

At 96 weeks: Adverse reactions (all grades) reported in ≥2% of participants were similar in both study arms, with few discontinuations due to adverse events (1% vs 2%). At ≥144 weeks: Safety profile similar to ≥96 weeks.

*When 100% of participants reached Week 48 and ≥50% reached Week 96.

When 100% of participants reached Week 96.

FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; MSM=men who have sex with men; OLE=open-label extension; PY=person-years; TGW=transgender women (who have sex with men).